openPR Logo
Press release

Researchers United to Find a HIV cure

04-15-2011 11:34 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Informed Horizons, LLC

HIV persistence is an area of importance to many scientists working on a possible cure for HIV, and every two years a reference workshop is held to bring the world's top scientists together for a meeting of the minds. Researchers from several different fields will therefore attend its next edition, December 6-9, 2011. The preliminary program of this workshop has just been released, and the four-day seminar is packed with intelligent dialogue and important research, all working toward the goal of eventual HIV cure.

Toulon, France, April 15, 2011 -- After the welcoming address given by Mario Stevenson (University of Miami, USA), the workshop is divided into blocks over the course of the next three days. These blocks, generally 90-120 minutes in length, feature several research abstracts pertaining to the same topic. This makes it very easy for guests to follow along with what's going on, and when.

On Wednesday, December 7, there are 3 blocks: ‘Models of HIV Persistence’, ‘Basic Science of HIV Persistence’, and a 2-hour presentation on the ‘Virological Aspects of HIV Persistence’. Included in these 3 blocks, as well as the others on subsequent days, are additional abstracts submitted by other scientists not scheduled to speak during the block.

On Thursday, December 8, several different blocks populate the longest day of the workshop. It starts at 8:00 am with ‘Innate Immunity & HIV Persistence’, followed by a 90-minute presentation on ‘Immune Control of HIV Reservoirs’. After an hour-long presentation from the firms supporting the workshop, the afternoon/evening session consists of two major blocks discussion about ‘Acute HIV Infection’ and ‘Anatomic HIV Reservoirs’. As before, additional abstracts will be discussed during the session block as time allows.

The final day, Friday, December 9, wraps things up with two morning presentation blocks on the ‘New Approaches Towards HIV Eradication’. These two discussion blocks are 2 hours each, separated by a half-hour break in between. The 8:00 session features such discussions about therapeutic intervention as it pertains to HIV infection and the various strategies targeting HIV reservoirs. The second 2-hour session, which is the final session of the workshop, is highlighted by two discussions on the CCR5 gene and the disruption of that gene that has yielded some important research in finding a possible cure for HIV.

The workshop will be closed by Doctor Alain Lafeuillade, MD and Françoise Barre-Sinoussi, 2008 Nobel Laureate for Medicine and International AIDS Society (IAS) President-Elect.

About the HIV Persistence Workshop:

The workshop will be closed by Doctor Alain Lafeuillade, MD and Françoise Barre-Sinoussi, 2008 Nobel Laureate for Medicine and International AIDS Society (IAS) President-Elect.

Alain Lafeuillade
Informed Horizons, LLC
General Hospital
Toulon, France

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Researchers United to Find a HIV cure here

News-ID: 171153 • Views:

More Releases from Informed Horizons, LLC

Scientists Move Towards A HIV Cure
Dr. Alain Lafeuillade and Dr. Mario Stevenson, are pleased to announce the 5th International Workshop on HIV Persistence During Therapy, to be held December 6-9, 2011 in St Maarten, West Indies. The Workshop will be of invaluable importance for scientists working towards a HIV cure. Toulon, France, May 29, 2011 -- Dr. Alain Lafeuillade, Toulon, France and Dr. Mario Stevenson, University of Miami, USA are pleased to announce the 5th International
Hope for a Cure Against HIV
Alain Lafeuillade (France) and Mario Stevenson (USA) co-authored a paper on HIV reservoirs that claims these reservoirs are the main hurdle to achieving HIV eradication. This paper provides information on the mechanisms of HIV persistence and a discussion on the critical questions facing researchers in the field. Tucker, GA, May 28, 2011 -- Alain Lafeuillade (France) and Mario Stevenson (USA) co-authored a paper on HIV reservoirs that claims these reservoirs are
New Discoveries Expected at the Scientific Workshop on HIV Reservoirs
Tucker, GA - April 21, 2011 -- Controlling HIV replication without the need of life-long antiretroviral therapy (ART) is the next frontier scientists are addressing. Researchers involved in the fields of HIV reservoirs and eradication have just released the preliminary program of a workshop they will organize later this year, where scientific breakthroughs are expected. Fifteen years ago, when ART was discovered, a renewed optimism for a cure gained several scientists

All 4 Releases

More Releases for HIV

HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral